Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street

Point Biopharma and Lantheus Holdings revealed topline results on Monday for their radioligand therapy in patients with metastatic castration-resistant prostate cancer who have progressed after treatment with an androgen receptor pathway inhibitor, showing encouraging results. But Point’s stock price nevertheless dropped following the announcement.